BR Biomedical Reports 2049-9434 2049-9442 D.A. Spandidos BR-22-3-01931 10.3892/br.2025.1931 Articles Elevated PTPN3 expression in type 2 diabetes mellitus: Insights from genetic and experimental analyses ChenShih-Yin 1 2 TsaiRu-Yin 3 4 TsengTo-Jung 3 4 ChenChin-Chang 3 4 School of Chinese Medicine, China Medical University, Taichung 404328, Taiwan, R.O.C. Genetics Center, Department of Medical Research, China Medical University Hospital, Taichung 404328, Taiwan, R.O.C. Department of Anatomy, School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan, R.O.C. Department of Medical Education, Chung Shan Medical University Hospital, Taichung 40201, Taiwan, R.O.C. Correspondence to: Professor Chin-Chang Chen, Department of Anatomy, School of Medicine, Chung Shan Medical University, 110 Section 1 Jianguo North Road, Taichung 40201, Taiwan, R.O.C. geoge6211@csmu.edu.tw guoxkl@163.com 03 2025 27 01 2025 22 3 53 20 09 2024 17 12 2024 Copyright © 2025, Spandidos Publications 2025

Type 2 diabetes mellitus (T2DM) is associated with chronic hyperglycemia, leading to severe complications, including increased risk of cancer. Protein tyrosine phosphatase non-receptor type 3 (PTPN3) is implicated in both T2DM and cancer progression. The aim of the present study was to investigate the role of PTPN3 genetic polymorphisms and expression in patients with T2DM, as well as to examine changes in body weight, blood glucose levels, and hepatic PTPN3 expression in db/db obese mice in comparison with control mice at 4, 16 and 32 weeks. A total of 469 patients with T2DM and 1,699 healthy control subjects were analyzed for PTPN3 genetic polymorphisms using blood samples. Additionally, the body weight of genetically diabetic obese db/db mice and genotype control mice, and their fasting blood glucose and PTPN3 mRNA and protein expression levels were assessed in the respective liver tissues at different stages of T2DM progression (4, 16 and 32 weeks) using reverse transcription-quantitative PCR, western blot and immunohistochemistry staining analyses. The allele C frequency of rs75235286 (82.1 vs. 79.1%, P=0.044) and allele G frequency of rs17202063 (82.8% vs. 79.5%, P=0.027) in PTPN3 SNPs differed significantly between T2DM patients and healthy controls. Additionally, the body weight of db/db mice and blood glucose levels were significantly increased from the 4th to 32nd week compared with control mice. Furthermore, db/db mice exhibited significantly elevated hepatic mRNA and protein expression levels of PTPN3 compared with control mice, especially at the 32nd week. Taken together, these findings suggested that an increased level of PTPN3 expression may serve a role in the progression of diabetic complications in patients with T2DM, highlighting the importance of further investigation into PTPN3 as a potential therapeutic target to decrease cancer risk and enhance treatment outcomes in T2DM.

 type 2 diabetes mellitus protein tyrosine phosphatase non-receptor type 3 allele frequency Funding: The present study was supported by Chung Shan Medical University, Taichung, Taiwan (grant no. RD11211) and China Medical University (grant no. CMU110-N-30). Introduction

Type 2 diabetes mellitus (T2DM) is characterized by sustained insulin resistance, increased insulin levels and chronic hyperglycemia. It affects 7.7% of adults in developed countries, with prevalence projected to increase by 20% in developed and 70% in developing countries by 2030, highlighting its status as a growing global health concern (1). Prolonged hyperglycemia causes severe damage to essential organs, increasing the risk of cardiovascular disease and diabetic microvascular complications, including atherosclerosis, diabetic nephropathy, retinopathy and neuropathy (1,2). Furthermore, hyperglycemia is a key factor linking T2DM with various types of cancer (3), including pancreatic, liver, breast, endometrial and colorectal cancer (4), as hyperglycemia has been demonstrated to promote the proliferation of cancer cells, resistance to cell death, and cancer cell migration and invasion (3). The development of T2DM is influenced by risk factors, including aging, diet, lifestyle changes and genetics. In 2007, Sladek et al (5) published the first genome-wide association study in the field of T2DM genetics, and identified at least 75 independent genetic loci associated with the disease; however, to date, there has been little focus on investigating genetic factors that may associate T2DM with cancer (6).

The protein tyrosine phosphatase non-receptor type 3 (PTPN3) is a non-transmembrane protein tyrosine phosphatase that serves a role in regulating the membrane cytoskeleton and signal transduction through the T cell antigen receptor (TCR). It is involved in the dephosphorylation of the TCR ζ subunit and the activation of nuclear factor-κB in T cells (7,8). A previous study showed that PTPN3 influences growth hormone receptor expression and systemic growth in mice by regulating insulin-like growth factor 1 secretion (9). Notably, abnormalities in PTPN3 expression are associated with the development and progression of numerous types of human cancer. For example, an increased level of PTPN3 expression was significantly associated with the differentiation and malignancy of human gastric adenocarcinoma (10). Furthermore, Gao et al (11) reported that activating mutations in PTPN3 gene increase proliferation and migration in cholangiocarcinoma cells, also noting an accelerated tumor recurrence in patients with intrahepatic cholangiocarcinoma. In a study that compared global gene transcript profiles between insulin-resistant and -sensitive non-diabetic individuals, Elbein et al (12) found that mRNA expression of PTPN3 was lower in insulin-resistant individuals compared with insulin-sensitive counterparts based on subcutaneous adipose tissue and muscle biopsy sample analyses. Furthermore, a significant increase in PTPN3 gene expression was observed in adipose tissues of patients with acromegaly, who exhibited higher levels of fasting plasma glucose and fasting insulin, and also a higher homeostasis model assessment-insulin resistance (HOMA-IR) index (13). Therefore, the present study aimed to investigate whether variations in PTPN3 genetic polymorphisms may serve a crucial role in the development of T2DM.

In the present study, PTPN3 genetic polymorphisms were examined in blood samples to identify significant differences between patients with T2DM and healthy control subjects. The BKS.Cg-Dock7m+/+ Leprdb/JNarl (db/db) mouse model has been widely used in diabetes research on the basis of the similarity of its pathological progression to that of T2DM (14,15). db/db mice harbor a spontaneous mutation in the leptin receptor gene (Lepr), which results in leptin resistance (16). Lepr genetic defect leads to inability to properly regulate energy balance, contributing to development of obesity, which is a major risk factor for T2DM in humans (17). By 4-6 weeks of age, db/db mice exhibit significant hyperphagia, obesity, hyperglycemia and hyperinsulinemia (18). Furthermore, db/db mice demonstrate diabetes-associated complications such as diabetic nephropathy, hepatic steatosis and cardiovascular disease, which are key for understanding the systemic impacts of T2DM (19). The comprehensive manifestation of T2DM-associated phenotypes makes db/db mice a robust preclinical model to investigate mechanisms underlying T2DM. Therefore, hepatic mRNA and protein levels of PTPN3 were assessed in both db/db and genotype control mice at 4, 16 and 32 weeks of age to analyze association between PTPN3 expression and the progression of T2DM.

 Materials and methods <sec> <title>Genotype analysis

A total of 469 patients diagnosed with T2DM (age, 40.5-84.0 years; male:female=51.3: 48.7) was enrolled for DNA genotype analysis through whole blood collection at China Medical University Hospital in Taichung, Taiwan, between August 2014 and July 2015. Patients with T2DM were selected according to the guidelines of the American Diabetes Association, as described previously (20). Briefly, diagnosis of diabetes was based on hemoglobin A1c ≥6.5% or fasting plasma glucose ≥126 mg/dl (7 mmol/l). Fasting was defined as no caloric intake for at least 8 h or 2-h plasma glucose ≥200 mg/dl (11.1 mmol/l) in the oral glucose tolerance test or a patient with classic symptoms of hyperglycemia or hyperglycemic crisis [random plasma glucose ≥200 mg/dl (11.1 mmol/l)]. Exclusion criteria were patients diagnosed with T1DM, maturity-onset diabetes of the young, or gestational diabetes. Genotype frequency data from 1,699 healthy controls were obtained from the Taiwan Biobank (taiwanview.twbiobank.org.tw). The single-nucleotide polymorphisms (SNPs) within the PTPN3 gene were identified using the National Center for Biotechnology Information SNP database (ncbi.nlm.nih.gov/snp). SNPs were selected using Tagger function (software.broadinstitute.org/mpg/tagger/server.html; accessed on 13 Jun 2017) with the additional criteria: i) Threshold minor allele frequency in the HapMap phase 3 and ii) Han Chinese in Beijing, China + Japanese in Tokyo, Japan population of 0.05 for ‘tag SNPs’. All the patients signed informed consent forms, and the study protocol was reviewed and approved by Ethics Committee/Institutional Review Board of China Medical University Hospital (approval no. CMUH103-REC2-071).

 Animal studies

A total of 24 male db/db mice (weighing 18-20 g (n=12) and +Dock7m/+Dock7m genotype control counterparts (n=12), all aged 4 weeks, were purchased from the National Laboratory Animal Center in Taipei, Taiwan. The animals were maintained in a temperature-controlled environment at 22±2˚C with 55±10% humidity, a 12/12-h light/dark cycle and had free access to a standard diet and water. As outlined in our previous study (21), db/db mice at the ages of 4, 16 and 32 weeks correspond to early, middle and late stages of T2DM, respectively. Mice were separated into six groups, representing three stages of T2DM (early, middle and late) for both the control and T2DM groups (n=4 mice/group). Blood samples for glucose measurement were obtained with a volume of 10 µl/mouse from the tail veins of the mice at the 4th, 16th and 32nd weeks after a 12-h fasting period. Blood glucose levels were measured using a glucose monitor (ONETOUCH® Ultra Plus Flex™ Meter; ONETOUCH, Inc.). At the end of the procedure, the mice were euthanized via a gradual introduction of CO2 starting at 30% of the chamber volume/min and increasing to 70% of the chamber volume/min, until mice were fully unconscious. To confirm death, cervical dislocation was performed after ensuring that the mice no longer responded to painful stimuli. Liver tissue was collected for further analysis. This animal study was approved by the Institutional Animal Care and Use Committee of China Medical University (approval no. 104-34-C-1).

 Reverse transcription-quantitative (RT-q)PCR assay

Total RNA was isolated from liver tissues using RNeasy® mini kit (Qiagen GmbH). cDNA synthesis was performed using a RevertAid™ First Strand cDNA Synthesis kit (Thermo Fisher Scientific, Inc.) following the manufacturer's instructions. cDNA was subjected to RT-qPCR analysis using an ABI ViiA™ 7 RT-PCR system (Thermo Fisher Scientific Inc.) with TaqMan® fluorophore-based probes (Thermo Fisher Scientific, Inc.) and universal probe #1 (cat. no. 04684974001; Roche Diagnostics). The primer sequences for PTPN3 (NM_011207.2) were as follows: forward, 5'-GAATGTTCTCTCTCAGTACTGGACTC-3' and reverse, 5'-CCTTTTTGCAATATTGGTTATTTACA-3'. GAPDH (M32599.1) served as the internal control, with probe #29 (cat. no. 04687612001). The GAPDH primer sequences were as follows: forward, 5'-GAGCCAAACGGGTCATCA-3' and reverse strand, 5'-CATATTTCTCGTGTTCACACC-3'. Thermocycling conditions were as follows: Initial denaturation at 95˚C for 5 min, followed by 25 cycles of 95˚C for 10 sec, 56˚C for 10 sec and 72˚C for 20 sec, and final extension at 72˚C for 5 min. The PCR data for PTPN3 were normalized to the GAPDH threshold cycle value and quantified using the comparative threshold cycle 2-ΔΔCq method (22).

 Western blot analysis

Frozen liver tissue (150 mg) was homogenized in 3 ml ice-cold 10 mM phosphate lysis buffer containing 0.25 M sucrose (pH 7.0), 1 mM EDTA, 0.1 mM PMSF and 1 mM sodium azide. The homogenate was centrifuged at 20,000 x g for 30 min at 4˚C. The protein concentration was determined using BCA assay. Subsequently, 40 µg/lane protein was separated by 8% SDS-PAGE and transferred to PVDF membranes. The PVDF membranes were incubated in 5% non-fat dry milk dissolved in Tris-buffered saline containing 0.1% TBS-T) at room temperature for 1 h to block non-specific binding. The membranes were incubated overnight at 4˚C with primary antibodies against PTPN3 (1:1,000; cat. no. GTX54572; GeneTex, Inc.) and secondary antibodies (1:5,000; cat. nos. #31430 and #31460; Thermo Fisher Scientific, Inc.) at room temperature for 1 h. The signals were visualized using an Enhanced Chemiluminescence kit (GE Healthcare) following the manufacturer's protocol, analyzed with ImageQuant 5.2 software (GE Healthcare), and normalized using β-actin (1:5,000; cat. no. ab8226; Abcam) as the internal control.

 Immunohistochemistry (IHC) staining analysis

Liver IHC staining was performed using a Leica Bond MAX automated immunostainer (Leica Microsystems, Inc.) as previously described (21). Briefly, tissue sections were dewaxed and treated with 3% H2O2 at room temperature for 10 min for blocking, followed by overnight incubation at 4˚C with a specific rabbit anti-human PTPN3 antibody (1:100; cat. no. GTX54572; GeneTex, Inc.). The sections were treated with a goat anti-rabbit HRP polymer (1:500; cat. no. #31460; Thermo Fisher Scientific, Inc.) for 30 min at room temperature. Chromogen visualization was achieved using DAB for 5 min, and the staining was observed under a light microscope (Leica DM 1000 LED Lab microscope; cat. no. 10052-384; Leica Microsystems, Inc.) at 100x and 400x magnifications.

 Statistical analysis

Genotype and allele frequencies of the PTPN3 SNPs rs75235286 and rs17202062 between patients with T2DM and healthy controls were assessed using χ2 test. Additionally, 95% confidence intervals for the odds ratios were calculated for the genotype and allele frequencies of PTPN3 SNPs rs75235286 and rs17202062. Data are presented as the mean ± SD of three independent experimental repeats. Differences were evaluated using one-way ANOVA followed by post hoc least significant difference test. Statistical analyses were performed using IBM SPSS Statistics 27.0 (IBM Corp.). P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Higher allelic frequency of PTPN3 SNPs rs75235286 and rs17202062 in patients with T2DM

A comparative analysis between SNPs in the PTPN3 gene of patients with T2DM and healthy control subjects revealed allele C at the rs75235286 site, and allele G at the rs17202062 site, within the chromosome region 9q31.3 of the PTPN3 gene (Fig. 1). Variants rs75235286 and rs17202062 were identified within chromosome region 9q31.1-9q31.3 in the PTPN3 gene (Fig. 1). Allele C frequency in the rs75235286 SNP of PTPN3 was significantly higher among patients with T2DM (82.1%; 770/938) compared with healthy controls (79.1%; 2688/3398; Table I). Similarly, the allele G frequency in rs17202062 SNP of PTPN3 among patients with T2DM (82.8%; 775/936) was significantly higher compared with that in healthy controls (79.5%; 2,698/3,392). However, the genotype frequencies for rs75235286 and rs17202062 SNP did not exhibit significant differences between the T2DM and healthy control groups.

 Significant increases in body weight and blood glucose levels in db/db mice compared to controls mice

The db/db mice exhibited a significant increase in body weight compared with the control group (Fig. 2A) at 16 and 32 weeks. Additionally, blood glucose levels in the db/db mice were significantly elevated from the 4th to the 32nd week. By the 32nd week, the blood glucose levels in db/db mice were >500 mg/dl (Fig. 2B).

 Elevated hepatic PTPN3 mRNA and protein expression in db/db mice

Hepatic mRNA levels of PTPN3 were significantly higher in db/db mice compared with the control mice (Fig. 3). Similarly, PTPN3 protein levels were significantly higher in liver tissues of db/db compared with control mice (Fig. 4). IHC staining data demonstrated a marked increase in hepatic PTPN3 expression in db/db mice compared to control mice. This increase was consistently observed across all evaluated time points, with clear localization of PTPN3 staining predominantly in hepatocytes. The intensity and extent of PTPN3 staining were visibly greater in db/db mice, indicating an upregulation of the protein in response to the diabetic condition. The most pronounced difference was observed at 32 weeks; db/db mice showed strong, widespread PTPN3 staining, whereas control mice exhibited minimal staining levels (Fig. 5).

 Discussion

T2DM is a multifaceted metabolic disorder with a notable genetic predisposition; understanding the role of epigenetic modifications is key in T2DM research. Additionally, there is a well-established connection between T2DM and development of cancer (23,24). Given the frequent occurrence of cancer in individuals with diabetes, it is essential to investigate the potential factors that connect these diseases. Several contributing elements, such as poor glycemic control, dyslipidemia and elevated levels of insulin-like growth factors, influence both T2DM and cancer development (4). Additionally, these factors adversely impact the effectiveness of cancer treatment. In the present study, patients with T2DM and db/db mice, a widely used T2DM animal model (14,15,25), exhibited increased levels of PTPN3 gene expression. As the PTPN3 gene is associated with a higher incidence of different types of cancer (10,11), an elevated expression of PTPN3 in T2DM may represent another crucial pathological connection between T2DM and cancer. To the best of our knowledge, the present study is the first to support this.

PTPN3 gene encodes the PTPN3 protein, which is an enzyme that is involved in cellular signaling pathways that regulate various processes, including cell proliferation, differentiation, mitosis, and potentially, oncogenic transformation (26). Hochberg et al (13) suggested that patients with acromegaly with higher PTPN3 expression in adipose tissues exhibit elevated fasting plasma glucose levels and fasting insulin levels and higher HOMA-IR scores compared with patients with non-functioning pituitary adenoma. PTPN3 is associated with growth hormone signaling and may perform a role in glucose homeostasis (9,27). Therefore, its upregulation may affect pathological development of T2DM. Additionally, this enzyme is involved in regulation of the plasma membrane cytoskeleton, TCR-associated signal transduction and T cell activation (7,8). A recent study has reported on the critical role of PTPN3 in modulating immune responses in cancer, especially via influencing the production of cytokines such as IL-6 and tumor necrosis factor-α (TNF-α) (28). Additionally, poorly regulated glucose metabolism and hyperglycemia in diabetic patients are often associated with higher levels of chronic inflammatory markers, including IL-1β, IL-6 and TNF-α (29-31). Immune response activation contributes to the development and progression of cancer cells (32). Based on the aforementioned findings, it was hypothesized that an increased expression of PTPN3 in patients with T2DM may lead to an imbalance in the immune system. This imbalance may disrupt regulation of both inflammatory and anti-inflammatory responses, potentially accelerating progression of T2DM. The present results do not align with the findings of Elbein et al (12), which indicated that PTPN3 expression is downregulated in both adipose and muscle tissues of insulin-resistant individuals, highlighting its potential role in insulin resistance and metabolic regulation pathways, it is important to consider that the therapeutic approach for patients with T2DM with elevated PTPN3 expression may require some adjustment. Further studies, including animal and clinical studies, are key to explore the effects of increased PTPN3 expression on pathological progression of T2DM.

Yin et al (33) demonstrated that p38γ promotes dephosphorylation of epidermal growth factor receptor via activating PTPN3 and silencing the p38γ/c-Jun/PTPN3 signaling pathway increases sensitivity of K-Ras mutant cells to tyrosine kinase inhibitors. Similarly, Gao et al (11) found that patients with intrahepatic cholangiocarcinoma with higher PTPN3 protein levels have increased recurrence rates of cancer. These findings suggested that PTPN3 requires co-factors such as p38γ to mediate its oncogenic effects. Furthermore, PTPN3 expression is markedly increased in cisplatin- and doxorubicin-resistant ovarian cancer cells and silencing PTPN3 restored drug-sensitivity and inhibited cancer cell migration, stemness and tumorigenicity (34). Individuals with T2DM are at heightened risk for various types of cancers and encounter additional challenges due to elevated PTPN3 levels, which are exacerbated by p38γ-induced phosphorylation. This not only increases cancer risk but also promotes drug resistance, complicating treatment. Strategies targeting PTPN3 or its phosphorylation pathway must address both diabetes and related oncogenic risks, while balancing effectiveness and safety. Therefore, medical strategies that focus on decreasing PTPN3 expression or p38γ-induced phosphorylation of PTPN3 could be beneficial for patients with T2DM with high PTPN3 levels. These approaches may decrease cancer incidence and improve drug resistance in this population. The present study primarily focused on the significant increase in PTPN3 expression in diabetic patients and db/db mice and the mechanistic role of PTPN3 in cancer development was not directly examined herein. However, previous studies support the involvement of PTPN3 in oncogenesis: PTPN3 mutations could promote tumor proliferation and migration in cholangiocarcinoma (11) and Wu et al (10) demonstrated that PTPN3 overexpression is associated with malignancy in gastric adenocarcinoma and with drug resistance in various types of cancer cell. Future studies should explore the functional role of PTPN3 in cancer development in patients with T2DM, including the effect on tumor growth and cancer-associated signaling pathways in diabetic models with elevated PTPN3 expression.

A limitation of the present study is the absence of comprehensive clinicopathological data for T2DM patients involved. This lack of information could introduce biases in interpreting the association between PTPN3 expression and the progression of T2DM. However, to reduce these potential biases, the study was designed with strict inclusion criteria, focusing solely on genetic polymorphism analysis and using a well-defined control group from the Taiwan Biobank. For future research, it is essential to include clinicopathological data such as age, BMI, disease stage and duration to clarify the role of PTPN3 in T2DM pathology and its potential association with cancer risk. Additionally, future studies should incorporate western blot analysis to measure PTPN3 levels in serum proteins from patients with T2DM and healthy controls to confirm the results obtained from the db/db mouse model and establish the association between PTPN3 expression and clinical outcomes. Furthermore, examining the expression of PTPN3 in additional tissue samples, such as adipose and muscle tissues, may reveal its broader impact on systemic effects of T2DM, demonstrating the association between T2DM, PTPN3 expression and cancer, potentially guiding therapeutic developments.

In conclusion, in the present study, expression of PTPN3 gene and protein was significantly elevated in patients with T2DM and db/db mice. Upregulated PTPN3 may contribute to progression of diabetic complications, cancer and drug resistance in patients with T2DM due to its interactions with other molecules, such as p38γ. The present findings suggest that the role of PTPN3 gene warrants further investigation.

 Acknowledgements

Not applicable.

 Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

 Authors' contributions

SYC, RYT and CCC performed the experiments and wrote the manuscript. SYC and CCC confirm the authenticity of all raw data. TJT analyzed data and constructed the figures. SYC and CCC conceived the study. All authors have read and approved the final manuscript.

 Ethics approval and consent to participate

The present study was approved by Ethics Committee/Institutional Review Board of China Medical University Hospital (approval no. CMUH103-REC2-071). Additionally, the animal study was approved by the Institutional Animal Care and Use Committee of China Medical University (approval no. 104 34 C 1).

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 Use of artificial intelligence tools

During the preparation of this work, AI tools were used to improve the readability and language of the manuscript or to generate images, and subsequently, the authors revised and edited the content produced by the AI tools as necessary, taking full responsibility for the ultimate content of the present manuscript.

 References GraySPJandeleit-DahmKThe pathobiology of diabetic vascular complications-cardiovascular and kidney diseaseJ Mol Med (Berl)9244145220182468762710.1007/s00109-014-1146-1 FaselisCKatsimardouAImprialosKDeligkarisPKallistratosMDimitriadisKMicrovascular complications of type 2 diabetes mellitusCurr Vasc Pharmacol1811712420203105711410.2174/1570161117666190502103733 RyuTYParkJSchererPEHyperglycemia as a risk factor for cancer progressionDiabetes Metab J3833033620142534981910.4093/dmj.2014.38.5.330 WojciechowskaJKrajewskiWBolanowskiMKręcickiTZatońskiTDiabetes and cancer: A review of current knowledgeExp Clin Endocrinol Diabetes12426327520162721968610.1055/s-0042-100910 SladekRRocheleauGRungJDinaCShenLSerreDBoutinPVincentDBelisleAHadjadjSA genome-wide association study identifies novel risk loci for type 2 diabetesNature44588188520071729387610.1038/nature05616 VincentEEYaghootkarHUsing genetics to decipher the link between type 2 diabetes and cancer: Shared aetiology or downstream consequence?Diabetologia631706171720203270531510.1007/s00125-020-05228-y HanSWilliamsSMustelinTCytoskeletal protein tyrosine phosphatase PTPH1 reduces T cell antigen receptor signalingEur J Immunol301318132520001082037710.1002/(SICI)1521-4141(200005)30:5<1318::AID-IMMU1318>3.0.CO;2-G YoungJABeckerAMMedeirosJJShapiroVSWangAFarrarJDQuillTAvan HuijsduijnenRHvan OersNSCThe protein tyrosine phosphatase PTPN4/PTP-MEG1, an enzyme capable of dephosphorylating the TCR ITAMs and regulating NF-kappaB, is dispensable for T cell development and/or T cell effector functionsMol Immunol453756376620081861423710.1016/j.molimm.2008.05.023 PileckaIPatrignaniCPesciniRCurchodMLPerrinDXueYYasenchakJClarkAMagnoneMCZaratinPProtein-tyrosine phosphatase H1 controls growth hormone receptor signaling and systemic growthJ Biol Chem282354053541520071792114310.1074/jbc.M705814200 WuCWChenJHKaoHLLiAFYLaiCHChiCLinWCPTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinomaAnticancer Res2616431649200616619586 GaoQZhaoYJWangXYGuoWJGaoSWeiLShiJYShiGMWangZCZhangYNActivating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patientsGastroenterology1461397140720142450312710.1053/j.gastro.2014.01.062 ElbeinSCKernPARasouliNYao-BorengasserASharmaNKDasSKGlobal gene expression profiles of subcutaneous adipose and muscle from glucose-tolerant, insulin-sensitive, and insulin-resistant individuals matched for BMIDiabetes601019102920112126633110.2337/db10-1270 HochbergITranQTBarkanALSaltielARChandlerWFBridgesDGene expression signature in adipose tissue of acromegaly patientsPLoS One10e012935920152608729210.1371/journal.pone.0129359 OhnoTShimizuMShirakamiYBabaAKochiTKubotaMTsurumiHTanakaTMoriwakiHMetformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-+Leprdb/+Leprdb micePLoS One10e012408120152587966610.1371/journal.pone.0124081 GuestPCRahmouneHCharacterization of the db/db mouse model of type 2 diabetesMethods Mol Biol191619520120193053569610.1007/978-1-4939-8994-2_18 ChenHCharlatOTartagliaLAGenetics of leptin and obesity: db/db mice as a model for human obesityNat Rev Genet131451552012 ChuaSCWhiteDWWu-PengXSPhenotype of fatty liver and diabetes in leptin receptor-deficient db/db miceJ Clin Invest97125812641996 KingAJThe use of animal models in diabetes researchBr J Pharmacol16687789420122235287910.1111/j.1476-5381.2012.01911.x SharmaKZiyadehFNHyperglycemia and diabetic complications: The role of TGF-β in the pathogenesis of diabetic nephropathyKidney Int48 (Suppl 52)S7S101995 American Diabetes AssociationDiagnosis and classification of diabetes mellitusDiabetes Care33 (Suppl 1)S62S6920102004277510.2337/dc10-S062 TangYHWangYHChenCCChanCJTsaiFJChenSYGenetic and functional effects of adiponectin in type 2 diabetes mellitus developmentInt J Mol Sci231354420223636233610.3390/ijms232113544 HuangTHChenCCLiuHMLeeTZShiehSHResveratrol pretreatment attenuates concanavalin A-induced hepatitis through reverse of aberration in the immune response and regenerative capacity in aged miceSci Rep7270520172857841010.1038/s41598-017-02881-z GiovannucciEHarlanDMArcherMCBergenstalRMGapsturSMHabelLAPollakMRegensteinerJGYeeDDiabetes and cancer: A consensus reportCA Cancer J Clin6020722120102058772810.2337/dc10-0666 BonagiriPRShubrookJHReview of associations between type 2 diabetes and cancerClin Diabetes3825626520203269947410.2337/cd19-0077 BogdanovPCorralizaLVillenaJACarvalhoARGarcia-ArumíJRamosDRuberteJSimóRHernándezCThe db/db mouse: A useful model for the study of diabetic retinal neurodegenerationPLoS One9e9730220142483708610.1371/journal.pone.0097302 TonksNKNeelBGCombinatorial control of the specificity of protein tyrosine phosphatasesCurr Opin Cell Biol1318219520011124855210.1016/s0955-0674(00)00196-4 NishadRMukhiDMenonRKPasupulatiAKGrowth hormone and metabolic homeostasisEMJ Diabet678872018 IwamotoNOnishiHMasudaSImaizumiASakanashiKMorisakiSNagaoSKogaSOzonoKUmebayashiMPTPN3 inhibition contributes to the activation of the dendritic cell function to be a promising new immunotherapy targetJ Cancer Res Clin Oncol149146191463020233758470910.1007/s00432-023-05250-8 StentzFBUmpierrezGECuervoRKitabchiAEProinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crisesDiabetes532079208620041527738910.2337/diabetes.53.8.2079 LeeHKimMJLeeIKHongCWJeonJHImpact of hyperglycemia on immune cell function: A comprehensive reviewDiabetol Int1574576020243946956610.1007/s13340-024-00741-6 PickupJCInflammation and activated innate immunity in the pathogenesis of type 2 diabetesDiabetes Care2781382320041498831010.2337/diacare.27.3.813 ChangSCYangWCVHyperglycemia, tumorigenesis, and chronic inflammationCrit Rev Oncol Hematol10814615320162793183310.1016/j.critrevonc.2016.11.003 YinNLeppAJiYMortensenMHouSQiXMMyersCRChenGThe K-Ras effector p38γ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylationJ Biol Chem292150701507920172873987410.1074/jbc.M117.779488 ZhouZLinZWangMWangLJiYYangJYangYZhuGLiuTIdentification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacyEur J Med Res291220243817304810.1186/s40001-023-01587-5

Schematic representation of the PTPN3 SNPs, rs75235286 and rs17202062, located in the chromosome region 9q31.3. PTPN3, protein tyrosine phosphatase non-receptor type 3; SNP, single nucleotide polymorphism.

Body weight and blood glucose levels in control and db/db mice. (A) Body weight and (B) blood glucose levels were recorded. Blood glucose levels were measured after a 12-h fasting period. **P<0.01 vs. control.

Hepatic PTPN3 mRNA expression. *P<0.05 or **P<0.01 vs. control. PTPN3, protein tyrosine phosphatase non-receptor type 3.

Hepatic PTPN3 protein expression levels. (A) Hepatic PTPN3 protein expression was assessed, with β-actin used as an internal control. (B) Relative fold-changes in hepatic PTPN3 protein levels. *P<0.05 or **P<0.01 vs. ctrl. Ctrl, control; PTPN3, protein tyrosine phosphatase non-receptor type 3.

Immunohistochemistry staining of hepatic PTPN3 protein tyrosine phosphatase non-receptor type 3 expression.

Genotypic and allelic frequencies of PTPN3 genetic polymorphisms in patients with T2DM and healthy controls.

dbSNP ID Genotype Patients with T2DM (n=469) (%) Healthy controls (n=1,699) (%) OR (95% CI) P-value
rs75235286 CC 320 (68.2) 168 (17.9) 1.23 (0.73-2.06) 0.095
  CT 130 (27.7) 554 (32.6) 0.96 (0.56-1.65)  
  TT 19 (4.1) 78 (4.6) Ref  
  C 770 (82.1) 2,688 (79.1) 1.21 (1.00-1.46) 0.044
  T 168 (17.9) 710 (20.9)    
rs17202062 CC 17 (3.6) 76 (4.5) 0.74 (0.43-1.28) 0.075
  CG 127 (27.1) 542 (32.0) 0.78 (0.62-0.98)  
  GG 324 (69.2) 1,078 (63.6) Ref  
  C 161 (17.2) 694 (20.5) 0.81 (0.67-0.98) 0.027
  G 775 (82.8) 2,698 (79.5) Ref  

CI, confidence interval; OR, odds ratio; T2DM, type 2 diabetes mellitus; PTPN3, protein tyrosine phosphatase non-receptor type 3; dbSNP, Database of single nucleotide polymorphisms.